XML 58 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Sumarry of cash balances

Aethlon Medical, Inc.		$	588,066
Exosome Sciences, Inc.			1,266,875
Consolidated Cash Balance		$	1,854,941

Research and development expenses

		December 31,				December 31,
		2013				2012
Three months ended		$	542,383			$	371,253
Nine months ended		$	1,178,488			$	1,034,335

X

- Definition

Research and development expenses

+ References

No definition available.

+ Details

Name:	aemd_ResearchAndDevelopmentExpensesTableTextBlock
Namespace Prefix:	aemd_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of cash and cash equivalents.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration